Completed PHASE2 INTERVENTIONAL 1-arm NCT00343044

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Sponsor: Benaroya Research Institute

Conditions Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer

Interventions Bevacizumab Topotecan

Updated 8 times since 2017 Last updated: Apr 29, 2015 Started: Jun 30, 2006 Primary completion: Jan 31, 2010 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. Benaroya Research Institute leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Benaroya Research Institute
Genentech, Inc.
GlaxoSmithKline

Data source: Benaroya Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States